Becton, Dickinson and Co. (BDX) is a publicly traded Healthcare sector company. As of May 20, 2026, BDX trades at $147.16 with a market cap of $39.22B and a P/E ratio of 37.18. BDX moved +0.07% today. Year to date, BDX is -26.14%; over the trailing twelve months it is -16.82%. Its 52-week range spans $141.82 to $251.99. Analyst consensus is buy with an average price target of $182.20. Rallies surfaces BDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BDX jumps after Q2 results, raised FY26 adjusted EPS guidance, new CFO named: BD reported fiscal Q2 2026 results and raised full-year adjusted EPS guidance to $12.52–$12.72 (from $12.35–$12.65) while reaffirming revenue growth expectations. BD also announced Vitor Roque as CFO effective May 7, 2026 after serving as interim CFO since December 2025.
| Metric | Value |
|---|---|
| Price | $147.16 |
| Market Cap | $39.22B |
| P/E Ratio | 37.18 |
| EPS | $3.95 |
| Dividend Yield | 1.05% |
| 52-Week High | $251.99 |
| 52-Week Low | $141.82 |
| Volume | 2.06M |
| Avg Volume | 0 |
| Revenue (TTM) | $21.37B |
| Net Income | $1.14B |
| Gross Margin | 46.79% |
10 analysts cover BDX: 0 strong buy, 5 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $182.20.